Fosamax Osteonecrosis of the Jaw Causation: Understanding the FDA Warning

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Occupational Exposure Concern

For decades, general health and science communication has served as a foundational pillar for public understanding of medication risks, emphasizing the importance of informed patient-provider dialogue. Within this legacy framework, broad awareness of adverse drug reactions has been cultivated, yet the translation of such knowledge into specific, actionable contexts—particularly those involving occupational or environmental exposure—remains an evolving challenge. The transition from a general health lens to a focused concern about bisphosphonate exposure, such as that associated with Fosamax, requires careful bridging. While the original health information paradigm addressed population-level safety, it did not routinely interrogate the nuanced pathways through which pharmaceutical agents might intersect with non-clinical settings. As we pivot toward occupational exposure concern, the central question shifts from passive patient receipt of medication to active, often prolonged, contact with the substance in manufacturing, handling, or disposal environments. This reframing acknowledges that the risk profile for osteonecrosis of the jaw, as highlighted by FDA warnings, may extend beyond the therapeutic context into settings where exposure is incidental or chronic. The legacy of general health communication thus provides the necessary vocabulary and cautionary precedent, but the occupational lens demands a more granular assessment of exposure duration, concentration, and route—factors that were not the primary focus of earlier public health messaging.

Bridging to Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse event: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves exposed bone in the maxillofacial region that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, with the exclusion of metastatic disease. The condition can cause pain, swelling, infection, and difficulty eating.

Pathophysiology and Mechanistic Evidence

The pathophysiology of bisphosphonate-related ONJ is not fully understood, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Mechanistically, bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which has high bone turnover rates and is subject to microtrauma from chewing, this suppression may impair the repair of microscopic damage and compromise the blood supply, leading to bone necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, further reducing blood flow to the jawbone. The FDA-approved labeling for Fosamax includes a warning about ONJ. The warning states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Risk Assessment

Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. The introduction of equivalent dose (ED) and threshold dose (TD) metrics may help predict ONJ risk. In one study, ED for each medication was standardized to the cumulative dose of four years of weekly oral alendronate use (14,560 mg) (https://pubmed.ncbi.nlm.nih.gov/40619534/). This suggests that cumulative exposure is a critical factor. Patients who develop ONJ after prolonged Fosamax use, especially in the absence of other major risk factors, may have a stronger case for causation. Conversely, patients with multiple risk factors, such as cancer or corticosteroid use, may have a more complex attribution. The timeline between exposure and documented harm is variable. ONJ can occur after months to years of bisphosphonate therapy, and the risk increases with duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling advises that for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance reflects the balance between fracture prevention and the risk of adverse events like ONJ. Patients who develop ONJ after shorter durations may have other contributing factors, such as dental procedures or infections.

FDA Warning and Clinical Management

The adequacy of warnings regarding Fosamax and ONJ is a key consideration for affected patients. The labeling includes a specific section (5.4) dedicated to ONJ, which describes the condition, associated risk factors, and management recommendations. However, the time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a clear timeline between exposure and documented harm. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that mild symptoms may not be specific to the drug. However, severe symptoms warrant discontinuation, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating a drug-specific effect. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used for osteoporosis and other bone conditions. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The FDA has issued warnings about this risk, and studies show that bisphosphonates can suppress bone turnover, impair healing, and reduce blood supply to the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ from Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer, chemotherapy, corticosteroids, poor oral hygiene, pre-existing dental disease, and longer duration of bisphosphonate use. The risk increases with cumulative exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation between Fosamax and ONJ determined?

Causation assessment considers the temporal relationship between Fosamax use and ONJ onset, cumulative dose, and presence of other risk factors. Studies use equivalent dose metrics to predict risk (https://pubmed.ncbi.nlm.nih.gov/40619534/). Patients with prolonged use and no other major risk factors may have a stronger causation link.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.